Related Experiment Video
Updated: Oct 17, 2025
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
An evaluative in vitro investigation of the delivery of cytarabine with RGD decorated solid lipid nanoparticles
Shelly Roselyn Van Eyssen1, Doga Kavaz1
1Bioengineering Department, Faculty of Engineering, Cyprus International University, Cyprus, Turkey.
Aim:
To synthesise cytarabine-loaded SLNs modified with the RGD peptide as a ligand, suitable for effective cancer therapy.
Methods:
SLNs were synthesised by the high shear, hot homogenisation technique. A 2 level 3 factor analysis was used in optimisation. Particle size, zeta potential, poly-dispersion index and surface morphology were measured. Drug encapsulation, drug release, release kinetics, nanoparticle stability and chemical structure were determined. LIVE/DEAD® Fluorescence Assay was used to qualify cytotoxicity and Tryphan Blue assay to quantify.
Results:
Cyt-SLNs exhibited a size of 161 ± 2.25 nm, a PDI of 0.49 ± 0.15 and a zeta potential of -19.8 mV. Entrapment fell at 88.87 ± 0.02% and release at 83.5 ± 0.95%. The in vitro release kinetics pointed towards a diffusion-based drug release mechanism. SLNs remained stable for 60 d. Cytotoxicity studies revealed that conjugation of the ligand with the RDG peptide resulted in a significant decrease in cell viability in both cell lines.
Conclusion:
Overall, the study suggests that RGD-SLN-cyt can be used for effective cancer therapy.
